中山圣湘海济生物医药

Sansure Haiji, a subsidiary of Sansure Biotech, is a biopharmaceutical company based in Zhongshan, China, specializing in the development and production of recombinant protein therapeutics. The company's primary focus is on human growth hormone (hGH) products, including its flagship recombinant human growth hormone (rhGH) for injection marketed under the brand name Haizhiyuan. Following its acquisition by Sansure Biotech in 2021, the company has leveraged its parent's molecular diagnostic expertise to enhance its endocrinology and growth disorder offerings. Sansure Haiji operates large-scale GMP manufacturing facilities and maintains a pipeline targeting both pediatric and adult growth-related indications. The company aims to provide high-quality, affordable biological drugs to the Chinese and international markets.